Sinomenine hydrochloride improves DSS-induced colitis in mice through inhibition of the Notch signaling pathway Authors: Linxia Xu, Wei Liu, Xixiang Huang, Tong Sun, Letian Mei, Man Liu, Zhi Ren, Meng Wang, Hailun Zheng, Qiangwu Wang, Dapeng Li, Qizhi Wang, Xiquan Ke Published: 2024 ABSTRACT AbstractObjectiveTo study the therapeutic effect of sinomenine hydrochloride (SH) on dextran sodium sulfate (DSS)-induced colitis in mice as an animal model and the changes of Notch signaling pathway in colon tissue of mice after treatment.MethodsTwenty-four mice were randomly divided into control group, model group, SH low-dose group (20 mg/kg) and SH high-dose group (60 mg/kg), with 6 mice in each group. Disease activity index (DAI), colonic mucosal injury index and colonic histopathological score were calculated. The expression levels of related genes, proteins in Notch signaling pathway and inflammatory factors were quantified.ResultsSH can significantly reduce the symptoms of colitis mice, and can significantly reduce the DAI score (Model: 3.44 ± 0.27; SH-20: 2.50 ± 0.18; SH-60: 1.89 ± 0.17; P < 0.001) and histopathological injury degree (Model: 7.67 ± 0.52; SH-20: 5.17 ± 0.75, P < 0.01; SH-60: 3.33 ± 0.52, P < 0.001). SH can down-regulate the expression levels of Notch1, NICD1, Jagged1 and Hes1 proteins in colon tissue of colitis mice (Model: 1.92 ± 0.16, 1.83 ± 0.21, 2.23 ± 0.22, 1.91 ± 0.17; SH-20: 1.56 ± 0.12, 1.39 ± 0.13, 1.58 ± 0.12, 1.38 ± 0.11; SH-60: 1.24 ± 0.09, 1.23 ± 0.10, 1.23 ± 0.11, 1.22 ± 0.09; P < 0.01), and reduce the contents of serum pro-inflammatory cytokines TNF-α, IL-1β and IL-6 (Model: 718.53 ± 81.81, 51.62 ± 2.80, 444.07 ± 67.77; SH-20: 544.72 ± 90.03, 34.10 ± 2.90, 345.43 ± 43.40; SH-60: 434.11 ± 71.75, 29.44 ± 3.70, 236.11 ± 29.35; P < 0.001).ConclusionThe therapeutic effect of SH on DSS-induced colitis in mice may be related to inhibiting the overactivation of Notch signaling pathway.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12876-024-03546-8.Keywords: Ulcerative colitis, Sinomenine hydrochloride, Notch signaling pathway, Disease activity index Introduction Ulcerative colitis (UC) is a chronic inflammatory bowel disease of multifactorial origin, which can be involved in both the colon and rectum [1]. The incidence of UC has been increasing year by year in recent years [2]. UC brings great pain to patients’ lives and it is one of the high-risk pathogenic factors for colorectal cancer [3, 4]. At present, the conventional treatment drugs for UC are mainly amino-salicylic acids, adrenal glucocorticoids and immunosuppressants, but these drugs have large side effects and low cure rate after long-term use. Sinomenine hydrochloride (SH) is a drug monomer, extracted from the stems of sinomena sinensis and trichosa sinensis. A large number of studies have found that it has pharmacological effects such as anti-inflammatory, immune regulation and oxygen free radical scavenging [5–7]. At present, SH has achieved good therapeutic effect in the treatment of kidney disease [8, 9], rheumatoid arthritis [10], systemic lupus erythematosus [11, 12] and other diseases closely related to inflammation and autoimmune imbalance. SH has the advantages of low price, low toxicity and easy intestinal absorption, and has no mutagenic activity on somatic cells, and there is no evidence of addiction [13]. Currently, a number of studies have shown that by inhibiting the conduction of Notch signaling pathway, a variety of disease models, including rheumatoid arthritis [14], systemic lupus erythematosus [15], systemic sclerosis [16] and autoimmune encephalomyelitis [17] can be effectively treated. This may be related to the over-activation of inflammatory response and immune imbalance common to these diseases. Inflammation is abnormally activated in both UC patients and UC animal models [18]. SH has strong anti-inflammatory [19] and immunomodulatory activities [20]. In recent years, there have also been relevant reports on the use of SH in the treatment of colitis [21], but its therapeutic effect and mechanism of action are still unclear. In this study, the therapeutic effect of SH on UC mice model induced by dextran sodium sulfate (DSS) was discussed, and on this basis, to explore the molecular mechanism of SH treatment of colitis from the perspective of regulating Notch signaling pathway and regulating the expression of related inflammatory factors, providing scientific basis for SH treatment of UC, and to promote the development of new drugs to treat UC. Materials and methods Materials DSS (MW:36000–50000, MP Biomedicals); Sinomenine hydrochloride (CAS: 6080-33-7, McLean Biochemical Technology Co., Shanghai); HES1 Ab-DF7569-100 ml (DF7569, Affinity Biosciences); Cleaved-Notch1 (Val1744) Antibody (AF5307, Affinity Biosciences); Notch1 Rabbit Polyclonal antibody (20687-1-AP, Proteintech); ACTB Rabbit pAb (AC006, ABclonal Technology); JAG1 Rabbit pAb (ABclonal Technology); Goat Anti-Rabbit IgG HRP (CAS: BL103A) (MAC Bio); Trizol (15596026CN, Thermo Feld Bio); DEPC (AM9915G, Thermo Feld Bio); Primer synthesis (Sangon Biotech); Marker (CAS:26616, Thermo Feld Bio); BCA protein concentration determination kit, RIPA Protein Lysate (Strong) (CAS: P0013B), Protease phosphatase inhibition mixture, SDS-PAGE Protein Loading Buffer (5X), SDS-PAGE Gel Preparation Reagent (CAS: P0012A), Western Dilute (CAS: P0023A-500 ml), Western Sealing Solution (CAS: P0023B-500 ml), Western Second Antibody Diluent (CAS: P0023D-500 ml), TBSTw(TBS with Tween-20)and Hypersensitive ECL chemiluminescence kit (Beyotime Biotechnology); qRT-PCR reaction kit, TNF-α, IL-1β and IL-6 Elisa kit (ABclonal Technology); Xylene (Sigma); Hematoxylin-eosin dye (Soleibao Bio, Beijing). Colitis model construction and treatment Wild-type male BALB/c mice were purchased from the Shandong Experimental Animal Center (Certificate: SCXK 2020-0005). Throughout the experiment, we followed the principles of randomization and blinding. Twenty‐four mice (weight, 20–22 g) were randomly divided into four groups: the normal control group (treatment with water) (Normal, n = 6), the model group (Model, n = 6), the sinomenine hydrochloride low dose treatment group (SH-20, n = 6), and the sinomenine hydrochloride high dose treatment group (SH-60, n = 6). In this experiment, by referring to the previous experimental results and the study of GAO T [22], two concentration gradients of low dose (20 mg/kg) and high dose (60 mg/kg) were finally selected to study SH treatment of DSS induced colitis in mice. Except for the normal control group, the remaining three groups of mice drank 4%DSS freely every day for 7 days and replaced the 4% DSS solution every two days. At the same time, the normal control group and the model group were administered 0.2mL of water by oral gavage every day, and the SH low dose and high dose groups were administered with 20 mg/kg and 60 mg/kg of drugs dissolved in 0.2 ml of pure water by oral gavage, respectively. The mice were given intragastric administration once a day for 7 consecutive days. After the end of intragastric administration on the 7th day, all mice were killed on the 8th day, and corresponding blood samples and colon samples were collected. According to the requirements of the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC), referring to the Animal Euthanasia methods recommended by Laboratory Animal Anaesthesia and AVMA Guidelines on Euthanasia, in this experiment, mice were anesthetized by intraperitoneal injection of ketamine (100 mg/kg). We need to make sure the animal is completely anesthetized (completely unconscious) before we start the procedure. In addition, CO2 was used to euthanize mice to reduce their suffering as much as possible [23, 24]. Disease activity index Occultic blood test was performed on the stool of mice from the first day of modeling until the appearance of naked blood stool, and corresponding records were made. According to Zhu L [25], disease activity index (DAI) was scored by the average of scores for weight loss, stool characteristics, and degree of blood in stool. Refer to Table 1 for specific scoring rules. Table 1DAI scoring scaleWeight loss (%)Stool characteristicsDegree of blood in stoolScore0Normal stool ballOccult negative01–5Formed but easy to adhere to the anusOccult blood deficiency positive (reagent light yellowish green)15–10Thin and softOccult blood positive (reagent is blue-green)210–15Watery but does not adhere easily to the anusStrong positive occult blood (reagent is dark blue-green)3> 15Diarrhea and adherence to the anusNaked bloody stool4 DAI scoring scale Colonic mucosal damage index With reference to the study of Tejal Gandhi [26], colonic mucosal damage index (CMDI) was scored by observing colonic intestinal wall congestion and edema, mucosal ulcer size and intestinal perforation of mice with naked eyes. CMDI scoring standards are shown in Table 2, as follows: Table 2CMDI scoring criteriaColonic visual appearanceScoreIntestinal mucosal structure was basically normal, and no obvious damage was observed under the naked eye0Only mild hyperemia and edema in the intestinal mucosa, but the mucosal surface was smooth without erosion and ulcer1Intestinal wall hyperemia and edema were obvious, the mucosal surface was rough, partly granular, and occasionally erosive or intestinal adhesion2Intestinal wall was highly congested and edema, extensive ulcer necrosis or adhesion, and the maximum longitudinal diameter of the ulcer surface was < 1 cm3On the basis of 3 points, the maximum longitudinal diameter of the ulcer surface is > 1 cm, or megacolon/intestinal perforation is present4 CMDI scoring criteria Hematoxylin eosin staining To put it simply, wax blocks are sliced, dewaxed, dyed, and then sealed with neutral gum, which is then dried for image acquisition under the microscope, and then the image is analyzed. Histological index (HI) After hematoxylin eosin staining, the histological injury and pathological score were performed under the microscope from four aspects: the degree of inflammation, the depth of lesion involvement, the degree of recess destruction and the scope of lesion [27]. HI scoring criteria are shown in Table 3 as follows: Table 3HI scoring criteriaInflammation levelDepth of lesionDegree of recess damageLesion range (%)ScoreNoNoNoNo0MildMucosal muscle layer is involvedOne third of the basal recess was destroyed≤ 251SevereMuscular involvementTwo-thirds of the basal recess was destroyed> 25and ≤ 502serous membrane is involvedOnly the intact surface epithelium can be seen under the microscope> 50and ≤ 753All surface epithelium is destroyed> 754 HI scoring criteria qRT-PCR Referring to previous experimental steps, we completed the qRT-PCR process by extracting total RNA, reverse transcription of RNA into cDNA, obtaining primer sequence and PCR amplification. Total RNA was isolated from the colon by trizol method with the reagent of Thermo Feld Bio. Primer sequences of Notch1 and β-Actin were selected by using NCBI-gene and Primer Bank together and verified by NCBI-Blast. Primer sequence is shown in (Table 4). Under the action of primers, RNA was reversely transcribed into cDNA and then amplified by PCR. Samples were normalized to the control housekeeping gene β-actin and reported according to the method of 2–ΔΔCt. The expression level of Notch1 gene in colon tissue of mice was detected by qRT-PCR. Table 4Polymerase chain reaction primers’ gene sequencesTarget genePrimer sequence(5’→3’)Notch1-Forward PrimerGATGGCCTCAATGGGTACAAGNotch1-Reverse PrimerTCGTTGTTGTTGATGTCACAGTβ-actin-Forward PrimerGGCTGTATTCCCCTCCATCGβ-actin-Reverse PrimerGGCTGTATTCCCCTCCATCG Polymerase chain reaction primers’ gene sequences Western blot analysis Using RIPA lysate and protease phosphatase inhibition mixture, the protein concentration was determined using the BCA protein assay kit (Beyotime Biotechnology) according to the instructions. According to SDS-PAGE gel kit instructions, the gel was prepared for use, followed by sample addition, electrophoresis, film transfer, multiple film washing, incubation of primary and secondary antibodies, and finally development. Then Photoshop or Image J software was used to process the protein strips and record the gray value of each strip. Then the expression of Notch signaling pathway protein in each group was obtained. Immunohistochemistry analysis The following procedures were followed: dewaxment, antigen repair, serum blocking, incubation of primary antibody, incubation of secondary antibody, addition of SA-HRP, color development, restaining, differentiation, blue return, dehydration, sealing, etc. Finally, the expression of Notch1, NICD1, Jagged1, Hes1 in colon tissue of mice in each group was observed by microscope. Enzyme linked immunosorbent assay The concentrations of TNF-α, IL-1β and IL-6 in serum of mice in each group were detected by double antibody sandwich enzyme-linked immunosorbent assay (ELISA). After the sandwich complex of antibody-antigen-enzyme-labeled antibody was formed on the surface of the microporous plate, the absorbance was measured, and the concentration of various inflammatory factors was calculated by making the calibration curve. Statistical analysis Before the experiment, α = 0.05, power(1-β) = 0.8, effect size f = 0.8 were selected. GPowerWin3.1.9.7 software was used to estimate the sample size. After comprehensive consideration of ethical factors, the sample size was finally determined to be 24, with the same sample size in each group and 6 in each group. The experimental data of each group were presented in the form of mean ± SD. The data were compared using One-way ANOVA, and the Tukey test was applied for multiple comparisons between the data. P < 0.05 was considered statistically significant. SPSS 26.0 software was used for all statistical analyses in this experiment. Result The inflammatory mouse model of ulcerative colitis was established successfully During the experiment, DAI was scored by weight change, fecal character and blood in stool. The results showed that on the third day of modeling, mice in the model group began to lose weight (Fig. 1-A), and on the fourth day, mice in the model group generally developed loose stool and blood in the stool. With the extension of treatment time, the body weight of mice in this group decreased progressively (Fig. 1-A), and the DAI increased progressively (Fig. 1-B). On the 7th day of medication, the mice in the model group were lethargic and lazy, their hair was wet and dirty, and all of them had bloody stool (Fig. 2-Model). After modeling, compared with the normal control group, the body weight of the model group was significantly decreased (P < 0.001), the DAI score was significantly increased (Model: 3.44 ± 0.27, P < 0.001), and the colon length was significantly shortened (Normal: 8.47 ± 0.58, Model: 5.47 ± 0.51, P < 0.001) (Fig. 1-A ~ D). SH promotes recovery from DSS-induced colitis in mice A Changes in the body weight of mice in each group during the experiment; B Change in DAI score; C, D Colon length of mice in each group; E, F Anatomical side view of the colon and colonic mucosal damage index score. Data are expressed in Mean ± SD, n = 6. Compared with the model group, *P < 0.05, **P < 0.01, ***P < 0.001 Blood and diarrhea in the stool of mice in each group after the experiment In addition, the lateral anatomy of the colon of mice in the model group showed severe intestinal bleeding, extensive hyperemia and edema of the intestinal wall, and the formation of large-scale ulcer lesions, and CMDI scores were significantly increased (Model: 3.87 ± 0.50, P < 0.001) (Fig. 1-E, F). Combined with hematoxylin eosin staining, colonic gland atrophy, crypt deformation, reduction or disappearance of mucous in goblet cells, abnormal infiltration of a large number of inflammatory cells at the base of crypt and formation of crypt abscess were observed in the model group under microscope (Fig. 3-A-Model), which were also typical pathological basis of UC colonic tissue [28]. These results indicate that the UC mouse model has been successfully established. Histopathological lesions of colon in mice in each group A HE staining pictures of colon tissue of mice in each group (200×, 50 μm bar, red arrow indicates “crypt abscess”); B Histopathological scores of colon in each group. Data are expressed in Mean ± SD, n = 6. Compared with the model group, *P < 0.05, **P < 0.01, ***P < 0.001 Sinomenine hydrochloride alleviates DSS induced colonic inflammation in mice During the experiment, low and high doses of SH were administered at the same time as modeling. The results showed that, compared with the model group, SH (low and high dose) intervention treatment could significantly reduce the DAI score of colitis mice (SH-20: 2.50 ± 0.18; SH-60: 1.89 ± 0.17; P < 0.001) (Fig. 1-B) and reduce the weight loss of colitis mice (P < 0.001) (Fig. 1-A). It inhibited colon shortening (SH-20: 6.18 ± 0.53, P < 0.05; SH-60: 7.20 ± 0.50, P < 0.01) (Fig. 1-C, D), significantly alleviated the visible intestinal damage of colitis mice, and significantly reduced CMDI scores (SH-20: 3.20 ± 0.44, P < 0.05; SH-60: 2.21 ± 0.32, P < 0.001) (Fig. 1-E, F). Compared with the low dose group, DAI score in the high dose group was significantly decreased (t = 5.719, P < 0.001) in a dose-dependent manner. At the same time, after SH intervention, especially in the high-dose treatment group, the overall structure of the colon mucosa of mice was intact, the intestinal mucosal epithelium was only slightly damaged, the submucosal edema was mild, and only a small amount of inflammatory cell infiltration was observed in the mucosa, which significantly reduced the pathological score of the colon histological injury of colitis mice compared with the model group (Model: 7.67 ± 0.52; SH-20: 5.17 ± 0.75, P < 0.01; SH-60: 3.33 ± 0.52, P < 0.001). Compared with the low dose group, the histological injury and pathological score of the high dose group decreased more significantly (t = 6.056, P < 0.01) (Fig. 3). All the above results showed that SH had significant therapeutic effect on DSS induced colitis in mice, and could significantly improve the symptoms of diarrhea, blood stool, weight loss, and shortened colon in colitis mice, significantly reduce the colon tissue edema and erosion, and reduce the risk of colon ulcer and perforation in colitis mice, and was conducive to maintaining the integrity of the colon general structure of colitis mice. Sinomenine hydrochloride can significantly inhibit the abnormal activation of Notch signaling pathway in DSS induced colitis mice qRT-PCR was used to detect and compare the differences in gene expression levels of Notch pathway receptor Notch1 in colon tissues of mice in all groups. The results showed that compared with the blank control group, the gene expression level of Notch1 receptor in colon tissues of mice in the model group was significantly increased (Normal: 1.02 ± 0.08, Model: 8.16 ± 0.41, P < 0.001) (Fig. 4-A). Compared with the model group, Notch1 gene expression in the colon of mice was significantly reduced after SH (low and high dose) intervention (SH-20: 4.12 ± 0.38, P < 0.001; SH-60: 2.49 ± 0.36, P < 0.001). Compared with low dose group, the gene expression level of Notch1 receptor in colon tissues of mice in high dose group was significantly decreased (t = 3.386, P < 0.01) (Fig. 4-A). Expression of genes and proteins related to Notch pathway in the colon of mice in each group A Relative gene expression of Notch1 receptor in colon tissues of mice in each group; B Western blot protein bands of four key pathway proteins of the Notch pathway in colon tissues of mice in each group; C Western blot was used to detect the expression of Notch1, NICD1, Jagged1 and Hes1 proteins in the colon tissues of mice in each group. Data are expressed in Mean ± SD, n = 6. Compared with the model group, *P < 0.05, **P < 0.01, ***P < 0.001 Western blot detection of key pathway proteins of Notch pathway in colon tissues of mice in each group showed that the expression levels of Notch1, NICD1, Jagged1 and Hes1 in colon tissues of mice in the model group were significantly increased compared with the blank control group (Model: 1.92 ± 0.16, 1.83 ± 0.21, 2.23 ± 0.22, 1.91 ± 0.17; P < 0.001) (Fig. 4-B, C). Compared with the model group, the expression levels of Notch1, NICD1, Jagged1 and Hes1 in colon tissue of mice were significantly decreased after intervention with SH (low and high dose) (SH-20: 1.56 ± 0.12, 1.39 ± 0.13, 1.58 ± 0.12, 1.38 ± 0.11; SH-60: 1.24 ± 0.09, 1.23 ± 0.10, 1.23 ± 0.11, 1.22 ± 0.09; P < 0.01). Compared with the low-dose group, the expression of 4 proteins in colon tissue of mice in the high-dose group was significantly decreased (t = 2.337, P < 0.05) (Fig. 4-B, C). At the same time, immunohistochemical detection of Notch1, NICD1, Jagged1 and Hes1 proteins in the colon tissues of colitis mice in each group was performed. The results showed that, compared with the normal control group, the expression levels of these four proteins were all increased in the colon tissues of the model group, and Notch1 and Jagged1 were mostly located on the cell membrane. NICD1 and Hes1 are mostly expressed in the nucleus. Compared with the model group, after SH (low and high dose) drug treatment, the expression of 4 proteins in colon tissue was decreased (Model: 4.62 ± 0.43, 5.36 ± 0.41, 5.23 ± 0.52, 4.90 ± 0.47; SH-20: 3.14 ± 0.32, 3.28 ± 0.33, 3.67 ± 0.42, 3.08 ± 0.36; SH-60: 2.20 ± 0.19, 2.33 ± 0.20, 2.42 ± 0.31, 2.00 ± 0.19; P < 0.01). Compared with the low-dose treatment group, the expression of these four proteins decreased significantly in the high-dose treatment group (t = 3.032, P < 0.05), which also showed a dose dependence (Fig. 5). Effect of SH on Notch pathway activity in colon tissue of colitis mice (200×, 50 µM bar) Sinomenine hydrochloride can significantly reduce the expression of TNF-α, IL-1β and IL-6 in mice with colitis The serum of mice in each group was tested for cytokines. The results showed that the contents of TNF-α (718.53 ± 81.81), IL-1β (51.62 ± 2.80) and IL-6 (444.07 ± 67.77) in serum of mice in the model group were significantly increased compared with the blank control group (TNF-α (164.61 ± 29.09), IL-1β (21.95 ± 1.56), IL-6 (32.78 ± 6.84)) (P < 0.001) (Fig. 6). This showed that the inflammatory process in the model group of mice was over-activated and the inflammatory response was intense. Compared with the model group, the contents of TNF-α, IL-1β and IL-6 in serum of mice in the low (TNF-α: 544.72 ± 90.03, IL-1β: 34.10 ± 2.90, IL-6: 345.43 ± 43.40) and high (TNF-α: 434.11 ± 71.75, IL-1β: 29.44 ± 3.70, IL-6: 236.11 ± 29.35) dose SH intervention groups were significantly decreased (P < 0.001) (Fig. 6), indicating that SH has significant anti-inflammatory activity and can effectively treat DSS induced colitis in mice by inhibiting inflammatory response. In addition, compared with the low-dose SH group, the inflammatory factors in the high-dose SH group decreased more significantly (TNF-α: t = 2.657, P = 0.015; IL-1β: t = 2.224, P = 0.038; IL-6: t = 4.408, P < 0.001) in a dose-dependent manner. Effect of SH on serum inflammatory cytokines in UC mice model The serum expression levels of TNF-α (A), IL-1β (B) and IL-6 (C) in mice in each group. Data are expressed in Mean ± SD, n = 6. Compared with the model group, *P < 0.05, **P < 0.01, ***P < 0.001 Discussion UC is a chronic intestinal inflammatory disease, often manifested by continuous and diffuse inflammatory changes in colorectal mucosa [29], mostly involving colorectal mucosa and submucosa [30]. With the continuous improvement of people’s living standards and changes in lifestyle, the incidence of UC has shown an increasing trend year by year [31]. The etiology of UC is still unclear, and it is believed to be the result of multiple factors such as genetic, immune, environmental and intestinal flora imbalance [32]. At present, the commonly used therapeutic drugs for UC include traditional drugs and biologics. Traditional drugs mainly include aminosalicylic acids (the main representative drugs are mesalazine), corticosteroid hormones and biological inhibitors such as azathioprine and cyclosporine. Mesalazine is often used as standard and maintenance treatment for uncomplicated mild to moderate colitis [33], but a large number of studies have found that more than half of patients will relapse soon after mesalazine discontinuation [34, 35]. The side effects of steroid hormones are widely known, and their long-term use has great side effects, which can involve various systems such as musculoskeletal, gastrointestinal, cardiovascular, endocrine, neuropsychiatric, skin, eye, and immune [36–38]. Long-term use of immunosuppressants has a significant inhibitory effect on immune function, resulting in a great decline in the body’s ability to resist foreign bacteria, which greatly increases the risk of infection in patients. In addition, the use of immunosuppressants is also one of the high-risk factors for serious damage to liver and kidney function [39]. In recent years, anti-TNF-α monoclonal antibodies such as infliximab and adalimumab have been gradually used in the treatment of UC patients, but their cost is high, and a large number of studies have shown that about 1/3 of patients show no response to the drug from the beginning of treatment, and the drug will gradually lose its effect on up to 1/4 of patients every year [40, 41]. Therefore, researchers are more and more committed to the development of new drug therapies for UC, which also makes the search for multi-signaling pathway, multi-target combination therapy has become an inevitable trend in the future treatment of UC. SH has good anti-inflammatory and immunomodulatory effects [42]. On the basis of the successful establishment of UC mouse model, we successfully found that SH can significantly reduce the DAI score of colitis mice, reduce colon shortening and alleviate colon histopathological damage. In the study, we found that starting from the third day of modeling, mice in the model group and in the low and high dose intervention treatment groups of SH began to lose weight successively. From the 4th day of modeling, these three groups of mice began to show diarrhea and blood in stool successively, but the weight loss of mice in the model group was the highest, and the symptoms of diarrhea and blood in stool were the earliest and most serious. Starting from the 6th day of modeling, the weight of mice in the model group still decreased progressively, the symptoms of diarrhea and blood in the stool worsened progressively, and the DAI score still increased progressively. However, the weight loss of mice subjected to the intervention of low and high doses of SH drugs began to flatten out, and the DAI score also tended to flatten out. This suggests that SH has a significant mucosal protective effect, indicating that SH can significantly improve DSS induced colitis in mice. Studies have shown that the expression of TNF-α is significantly increased in UC patients, and the expression of TNF-α in inflammatory sites of intestinal mucosa is significantly higher than that in non-inflammatory sites [43], and the increase of TNF-α content has been proved to be positively correlated with the severity of UC [44]. Infliximab, which has been widely used to treat inflammatory bowel disease including UC in recent years, is one of the anti-TNF-α monoclonal antibodies [45]. IL-1β can induce neutrophil proliferation and promote neutrophil migration [46]. In addition, based on in-depth studies of IL-6 biological activity, studies have shown that targeted regulation of IL-6 expression can be used to treat inflammatory and autoimmune diseases [47]. In this study, compared with the normal control group, the expression levels of TNF-α, IL-1β and IL-6 in serum of the model group were significantly increased. Compared with the model group, SH could significantly inhibit the expression of TNF-α, IL-1β and IL-6 in serum of colitis mice, and the difference was statistically significant. This indicates that SH can significantly reduce intestinal inflammation and is conducive to intestinal mucosal healing. Notch signaling pathway is closely related to autoimmunity and inflammation in the body [48–50], and is a well-known pro-inflammatory signaling pathway [14, 51, 52]. Among all Notch receptors, Notch1 is the most widely distributed, and it is also the major receptor involved in maintaining intestinal homeostasis in the Notch pathway [53, 54]. Studies have shown that the expressions of Notch1 and Jagged1 in the colon are significantly increased when colon inflammation occurs [55]. After effective intervention, the expression level of Hes1 in the colon of colitis mice will decrease significantly [56]. Our study also found that compared with the normal control group, the Notch pathway receptor Notch1 gene expression was significantly increased in DSS induced colitis mice, and the expression levels of key pathway proteins Notch1, NICD1, Jagged1 and Hes1 were also significantly increased. This suggests that the Notch signaling pathway in colitis mice is abnormally overactivated. After intervention with low and high doses of SH, the receptor Notch1 gene expression decreased significantly, and the expression levels of Notch1, NICD1, Jagged1 and Hes1 also decreased significantly compared with the model group, and the relevant differences were statistically significant. It is suggested that SH may treat UC by inhibiting Notch pathway activity. In recent years, it has been reported that Qingbai Decoction [57], compound alfalfa decoction [58] and Gegen Qinlian decoction [56] can play a significant role in the treatment of colitis in mice by inhibiting Notch signaling pathway, which is consistent with our current research results. Our above research results show that SH can inhibit the secretion and expression of the downstream pro-inflammatory cytokines TNF-α, IL-1β and IL-6 by inhibiting Notch signaling pathway, thus alleviating intestinal inflammation, treating and relieving mucosal immune disorders, and promoting tissue repair, and has a protective effect on colitis mice. This suggests that SH holds promise as a potential preventive or therapeutic agent for patients with UC. However, this study only demonstrates that SH can effectively reduce intestinal inflammation and has a protective effect on colitis mice from the perspective that SH can effectively inhibit Notch signaling pathway, which has certain limitations. We need to further study its detailed molecular mechanism by increasing in vitro experiments and other methods. Our group will continue to explore whether SH plays a role in the treatment of UC by affecting other signaling pathways such as Wnt/β-catenin and miRNAs. In addition, UC is a chronic disease that can last for decades, so we need to evaluate the long-term effectiveness and drug safety of SH over a longer period of time. We have begun to continue to explore the optimal therapeutic dose of SH for the treatment of DSS-induced colitis, and provide necessary support and data for the clinical trial phase by studying the safety, dose effect, pharmacokinetics, drug interactions and other characteristics of SH. But at present, our current research is limited to the animal experimental stage, and we still have a long way to go from animal experiments to clinical trials. Conclusion In conclusion, we successfully established a mouse model of DSS induced colitis. In the study, we found that SH can significantly reduce the symptoms of colitis mice, and can significantly reduce the DAI score and histopathological injury degree. SH can down-regulate the expression levels of Notch1, NICD1, Jagged1 and Hes1 proteins in colon tissue of colitis mice, and reduce the contents of serum pro-inflammatory cytokines TNF-α, IL-1β and IL-6. This suggests that SH has a significant therapeutic effect on DSS induced colitis in mice, and its mechanism may be related to inhibiting the overactivation of Notch signaling pathway and inhibiting the expression of pro-inflammatory factors. Supplementary Information Supplementary Material 1. Acknowledgements I would like to thank the Laboratory of Respiratory and Critical Care Medicine of the First Affiliated Hospital of Bengbu Medical University for providing me with the experimental platform and many teachers in the laboratory for their help during the experiment. Abbreviations Sinomenine hydrochloride Ulcerative colitis Disease activity index Dextran sodium sulfate Histological index Colonic mucosal damage index One-way analysis of variance Tumor necrosis factor-α Interleukin-1β Interleukin-6 Authors’ contributions XK provided experimental ideas and revised manuscripts; LX designed experiments, completed experiments and wrote manuscripts; WL, XH, TS, LM and ML assist in the experiment; ZR, MW, HZ, QW, DL, and QW assist in experimental supervision and interpretation of data. All authors read and approved the final manuscript. Funding This study was supported by grants from Anhui Provincial Key Research and Development Project (No.2022a05020022) and the Program for Natural Science Research Project of Anhui Educational Committee (No.KJ2018A0217) and for Natural Science Research Project of Anhui Educational Committee(No. KJ2021A0813) and Science and Technology Development Fund Project of the First Affiliated Hospital of Bengbu Medical University (No.Byyfykj201804). Data availability All data included in this study can be obtained by contacting the corresponding author. Declarations Ethics approval and consent to participate This study has been approved by the Animal Ethics Committee of Bengbu Medical University (No.2021336). All experiments were conducted in accordance with relevant guidelines and regulations. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement All data included in this study can be obtained by contacting the corresponding author.